Outcomes

To characterize the three scenarios (fast, intermediate, and slow) we derived the following outcomes:

Time to complete remission (CR): Complete remission: blast fraction ≤5% [5]. We measured time in days from diagnosis to first time CR.

Duration of CR: In case of a CR, we measured time from CR to relapse (blast fraction > 5%) or respectively until all HSC are depleted. In our simulations we used a threshold that set cell counts (c₁, c₂, l₁, l₂) to zero if they are respectively below one cell (here, < 1/70). We consider such a situation as complete loss of normal hematopoiesis that very probable leads to death. If none occurs (neither relapse nor loss of normal hematopoiesis), the time from CR until the end of the simulation run was reported (2000 days, 5000 days for the slow pace leukemia).

Therapeutic width: Therapy combinations will vary in their effectiveness. We thus also report the relative frequency of therapy combinations leading to a CR (therapeutic width), as well as the relative frequency of therapy combinations resulting in under- and overtreatment, respectively.

Resulting outcomes will be presented as heatmap figures in the manuscript. Outcome data is contained in Additional file 3.